Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Faes Farma, S.A. is a publicly traded Spanish pharmaceutical company founded in 1933, specializing in the research, development, production, and marketing of pharmaceutical products, healthcare items, over-the-counter medicines, food supplements, personal care treatments, and raw materials for the pharmaceutical industry. Headquartered in Leioa, Biscay, Spain, it operates through key segments including Pharmaceutical and Healthcare Specialties, Animal Nutrition and Health via its FARM Faes division, and Pharmaceutical Raw Materials. The company addresses diverse therapeutic areas such as cardiovascular, respiratory, central nervous system, allergy, venous insufficiency, metabolic disorders, ophthalmic conditions, osteoporosis, and irritable bowel syndrome. With approximately 1,775 employees, Faes Farma maintains a strong international footprint, exporting to over 100 countries, particularly growing in Latin America and Africa, while conducting most business in Spain and Portugal. Recent expansions include a state-of-the-art 60,000 m² factory in Derio to enhance production capacity and support its role as a global player in the healthcare sector.
€4.65
+€0.08 (+1.75%)
EOD Jun 23, 2026 · Twelve Data
14.92% operating margin is respectable but not wide. ROIC at 8.85%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue grew 23.7%, still solid. Margins contracted 7.4pp, which offsets some of the top-line progress.
Free cash flow declined 28% versus the prior year, cash generation momentum has weakened. ROIC dropped from 15.32% to 8.85%, capital efficiency is deteriorating.
18.3x earnings, 26.4x FCF. Valuation is in a reasonable range. The main question is whether the business can re-accelerate or if current trajectory is already priced in.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€610M
▲ +23.7% YoY
Net Income (TTM)
€80M
▼ -28.3% YoY
Op. Margin
14.92%
▼ -7.4pp YoY
ROIC
8.85%
▼ -6.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€55M
▼ -27.7% YoY
Op. Cash Flow (TTM)
€57M
▼ -36.4% YoY
Net Debt
€295M
Cash & Equiv.
€130M
3Y CAGR: +11.6%
3Y CAGR: +28.1%
Continue Research